Abstract
The zebrafish (Danio rerio) histamine H1 receptor gene (zfH1R) was cloned in 2007 and reported to be involved in fish locomotion. Yet, no detailed characterization of its pharmacology and signaling properties have so far been reported. In this study, we pharmacologically characterized the zfH1R expressed in HEK-293T cells by means of [3H]-mepyramine binding and G protein-signaling assays. The zfH1R [dissociation constant (KD), 0.7 nM] displayed similar affinity for the antagonist [3H]-mepyramine as the human histamine H1 receptor (hH1R) (KD, 1.5 nM), whereas the affinity for histamine is 100-fold higher than for the human H1R. The zfH1R couples to Gαq/11 proteins and activates several reporter genes, i.e., NFAT, NFϰB, CRE, VEGF, COX-2, SRE, and AP-1, and zfH1R-mediated signaling is prevented by the Gαq/11 inhibitor YM-254890 and the antagonist mepyramine. Molecular modeling of the zfH1R and human H1R shows that the binding pockets are identical, implying that variations along the ligand binding pathway could underly the differences in histamine affinity instead. Targeting differentially charged residues in extracellular loop 2 (ECL2) using site-directed mutagenesis revealed that Arg21045x55 is most likely involved in the binding process of histamine in zfH1R. This study aids the understanding of the pharmacological differences between H1R orthologs and the role of ECL2 in histamine binding and provides fundamental information for the understanding of the histaminergic system in the zebrafish. SIGNIFICANCE STATEMENT: The use of the zebrafish as in vivo models in neuroscience is growing exponentially, which asks for detailed characterization of the aminergic neurotransmitter systems in this model. This study is the first to pharmacologically characterize the zebrafish histamine H1 receptor after expression in HEK-293T cells. The results show a high pharmacological and functional resemblance with the human ortholog but also reveal interesting structural differences and unveils an important role of the second extracellular loop in histamine binding.
Original language | English |
---|---|
Pages (from-to) | 84-96 |
Number of pages | 13 |
Journal | Molecular Pharmacology |
Volume | 105 |
Issue number | 2 |
Early online date | 10 Jan 2024 |
DOIs | |
Publication status | Published - 1 Feb 2024 |
Bibliographical note
Publisher Copyright:Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics.
Funding
D.A.M.-F. held a scholarship (359438) from CONACyT. The authors acknowledge The Netherlands Organisation for Scientific Research (NWO) for financial support [TOPPUNT, “7 ways to 7TMR modulation (7-to-7),” 718.014.002] (to R.L.) and Jane and Aatos Erkko Foundation (JAES) and Magnus Ehrnrooth’s Foundation (to P.P.). D.A.M.-F. held a scholarship (359438) from CONACyT. The authors acknowledge The Netherlands Organisation for Scientific Research (NWO) for financial support [TOPPUNT, “7 ways to 7TMR modulation (7-to-7),” 718.014.002] (to R.L.) and Jane and Aatos Erkko Foundation (JAES) and Magnus Ehrnrooth’s Foundation (to P.P.). The authors thank H.F. Vischer for the technical advice on the generation of the mutants and I. Slynko for her initial approach docking histamine binding docking on zebrafish H1R and performing the histamine simulations.
Funders | Funder number |
---|---|
Consejo Nacional de Ciencia y Tecnología | |
Nederlandse Organisatie voor Wetenschappelijk Onderzoek | 7-to-7, 718.014.002 |
Jane ja Aatos Erkon Säätiö | |
Magnus Ehrnroothin Säätiö |